‘Angels in the sky': Doctor saves man's life during flight
OKLAHOMA (KOCO) -- An Oklahoma doctor saved a man's life during a flight in April, using his medical expertise and a special tool to keep the passenger safe.
T.J. Trad, an invasive cardiologist with Stillwater Medical Center, detailed the moments and how he used a portable EKG monitor to stabilize the passenger experiencing chest pain.
'He was very anxious, he said, and 'I'm going to die,' and the first thing that came to my mind was, 'Not today,'' said Trad.
Trad was returning to the U.S. after working with about 100 patients for free through his organization, Cura for the World and Project Orphans, when a passenger began experiencing chest pain.
Courtney Wood, a nurse travelling with Dr. Trad, alerted him to the situation, prompting him to immediately assist the passenger. Dr. Trad used a KardiaMobile Card, a portable EKG monitor, to assess the man's condition 30,000 feet in the air.
'I asked him on a scale from 0-10, 10 being the most intense pain you've ever had. He said, 'I'm at a 10,'' Trad said.
Working with other healthcare professionals on board, they managed to reduce the man's pain to zero within about 30 minutes and kept him stable until the plane landed in Amsterdam.
'The nurse that was sitting at bedside, she was getting vitals every 5-10 minutes. So, she was getting his heart rate, his pulse ox, his blood pressure, and she was documenting that on a piece of paper,' Trad said. 'They gave me a seat right next to the door, where the pilot is, so that I can give him updates.'
Reflecting on the incident, Dr. Trad described it as a full-circle moment, having experienced a heart attack himself while working to save another life.
'You try your best to act very fast during moments like that, but having felt what this patient had felt, or what other patients had felt, makes me a better doctor, a lot more compassionate, a lot more empathetic,' he said.
The patient, who spent the night in the hospital and was discharged the next day, is reportedly doing OK.
Trad humbly attributed the successful outcome to divine intervention.
'His wife hugged me, and she said we were her angels in the sky, and that was very, very sweet,' he said.
Dr. Trad advises travellers to carry items like nitroglycerin or aspirin in case of a cardiovascular emergency. He remains focused on his foundation's clinics, including one in Creek County.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Manfred Stapff's Breakthrough Book Hits #1 on Amazon, Tackles Misinformation with Real-World Evidence
Summary: Dr. Manfred Stapff's newly released book, Real-World Evidence Unveiled: Navigating the Maze of Modern Misinformation, has soared to #1 on Amazon in multiple categories. New York, New York--(Newsfile Corp. - June 5, 2025) - Candid-Advisory founder and renowned physician-scientist Dr. Manfred Stapff has made a notable impact in the publishing world with the release of his new book, Real-World Evidence Unveiled: Navigating the Maze of Modern Misinformation. Since its debut on April 23, 2025, the book has become an Amazon bestseller, currently ranked #1 in multiple categories, including Anthropology, Civil Rights and Liberties, Social Theory, Sociology Research and Measurement, Communication Reference, and Social Sciences Research. Image Credit: Real-World Evidence Unveiled by Dr. Manfred Stapff To view an enhanced version of this graphic, please visit: Dr. Stapff's much-needed book has arrived at a time when society is flooded with misleading headlines, viral misinformation, and biased reporting. Through Real-World Evidence Unveiled, he introduces readers to the concept of Real-World Evidence (RWE). This is a powerful approach based on real-life data rather than experimental trials or curated information. Though the term is rooted in healthcare, Stapff broadens its scope to help readers evaluate news, social media narratives, and policy debates through an evidence-based lens. With this book, Stapff refines and filters years of work in regulatory science, quality management, and global medical operations by turning it into an accessible guide for students, professionals, and informed citizens alike. He uses compelling case studies and practical strategies, using the book to show readers the way to distinguish reliable data from noise, break down media narratives, and apply critical thinking in everyday life. Real-World Evidence Unveiled is already earning praise across academic, corporate, and consumer audiences as it continues to climb bestseller charts. The book has become a must-read for anyone interested in truth, transparency, and data-driven thinking. Misinformation prevails in public health, democracy, and social cohesion; Real-World Evidence Unveiled is a warning and a solution. It reminds readers that rigorous thinking and sound data are not just tools for scientists but the foundation of a functional society. About the Author Dr. Manfred Stapff, MD, PhD, is the founder of Candid-Advisory and a leader in clinical research, regulatory science, and real-world data analytics. His career spans over three decades, including senior roles in top pharmaceutical firms across Germany and the United States. He helps individuals and organizations make informed, evidence-based decisions. About Candid-Advisory Candid-Advisory is a life sciences consultancy that offers expert solutions in clinical trials, regulatory affairs, quality management, and real-world data utilization. Headquartered in New York and Boston, the firm partners with healthcare innovators to deliver strategic, unbiased counsel across therapeutic areas and business functions.
Globe and Mail
2 hours ago
- Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine. Current Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC. Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term. Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide. Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space. Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer. New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine. Patent expected to be Orange Book Listable. Waiver Exemption from Paying a $4.3 Million New Drug Application Fee Under Prescription Drug User Fee Act (PDUFA). Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties. Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100. In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management. NRXP anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen's petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression. Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. Kadima is one of California's flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine On May 5th NRXP announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment and methods of manufacture and currently includes twenty claims. While subject to the patent review process of the US Patent and Trademark Office, if granted, the patent would provide NRX-100 exclusivity into 2045. This patent filing builds on the NRXP recently initiated filing of an NDA for NRX-100 and its prior Fast Track Designation, with NRX-101, from the FDA. If granted, the patent will help protect the innovation behind this formulation as NRXP advances its commercialization strategy. "We are committed to delivering safer, more effective treatments for patients with suicidal depression," said Jonathan Javitt MD MPH, CEO of NRXP. "NRX-100 eliminates the need for benzethonium chloride, a compound with well-documented safety concerns, and reflects our belief that patients in crisis deserve therapies formulated with their long-term well-being in mind. With the recent FDA fee waiver now in place, we remain on track to complete our NDA submission this quarter — a critical step toward bringing this innovation to patients in need." FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression On April 30th NRXP announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. NRXP anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025). Disclosure listed on the CorporateAds website Media Contact Company Name: NRx Pharmaceuticals, Inc. Contact Person: Matthew Duffy, Chief Business Officer Email: Send Email Phone: 484 254 6134 Address: 1201 Orange Street Suite 600 City: Miami State: Florida Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
How Trump's travel ban could affect the upcoming FIFA World Cup and Summer Olympics
U.S. President Donald Trump often says the 2026 World Cup and 2028 Los Angeles Olympics are among the events he is most excited about in his second term. Yet there is significant uncertainty regarding visa policies for foreign visitors planning trips to the U.S. for the two biggest events in sports. Trump's latest travel ban on citizens from 12 countries added new questions about the impact on the World Cup and the Summer Olympics, which depend on hosts opening their doors to the world. Here's a look at the potential effects of the travel ban on those events. When Sunday ticks over to Monday, citizens of 12 countries should be banned from entering the U.S. They are Afghanistan, Myanmar, Chad, the Republic of Congo, Equatorial Guinea, Eritrea, Haiti, Iran, Libya, Somalia, Sudan and Yemen. Tighter restrictions will apply to visitors from seven more: Burundi, Cuba, Laos, Sierra Leone, Togo, Turkmenistan and Venezuela. Trump said some countries had 'deficient' screening and vetting processes or have historically refused to take back their own citizens. Explainer: What is Trump's new travel ban and which countries are affected? Here's what to know Iran, a soccer power in Asia, is the only targeted country to qualify so far for the World Cup being co-hosted by the U.S., Canada and Mexico in one year's time. Cuba, Haiti and Sudan are in contention. Sierra Leone might stay involved through multiple playoff games. Burundi, Equatorial Guinea and Libya have very outside shots. But all should be able to send teams to the World Cup if they qualify because the new policy makes exceptions for 'any athlete or member of an athletic team, including coaches, persons performing a necessary support role, and immediate relatives, travelling for the World Cup, Olympics, or other major sporting event as determined by the secretary of state.' About 200 countries could send athletes to the Summer Games, including those targeted by the latest travel restrictions. The exceptions should apply to them as well if the ban is still in place in its current form. Trump travel ban could damage longstanding relations with African countries, leaders warn The travel ban doesn't mention any exceptions for fans from the targeted countries wishing to travel to the U.S. for the World Cup or Olympics. Even before the travel ban, fans of the Iran soccer team living in that country already had issues about getting a visa for a World Cup visit. Still, national team supporters often profile differently to fans of club teams who go abroad for games in international competitions like the UEFA Champions League. For many countries, fans travelling to the World Cup – an expensive travel plan with hiked flight and hotel prices – are often from the diaspora, wealthier, and could have different passport options. A World Cup visitor is broadly higher-spending and lower-risk for host nation security planning. Visitors to an Olympics are often even higher-end clients, though tourism for a Summer Games is significantly less than at a World Cup, with fewer still from most of the 19 countries now targeted. FIFA president Gianni Infantino has publicly built close ties since 2018 to Trump – too close according to some. He has cited the need to ensure FIFA's smooth operations at a tournament that will earn a big majority of the soccer body's expected $13-billion revenue from 2023-26. Infantino sat next to Trump at the White House task force meeting on May 6 which prominently included Secretary of Homeland Security Kristi Noem. FIFA's top delegate on the task force is Infantino ally Carlos Cordeiro, a former Goldman Sachs partner whose two-year run as U.S. Soccer Federation president ended in controversy in 2020. Any visa and security issues FIFA faces – including at the 32-team Club World Cup that kicks off next week in Miami – can help LA Olympics organizers finesse their plans. 'I don't anticipate any, any problems from any countries to come and participate,' LA Games chairman Casey Wasserman told International Olympic Committee officials in March. He revealed then, at an IOC meeting in Greece, two discreet meetings with Trump and noted the State Department has a 'fully staffed desk' to help prepare for short-notice visa processing in the summer of 2028 – albeit with a focus on teams rather than fans. 'Irrespective of politics today,' Wasserman said in March, 'America will be open and accepting to all 209 countries for the Olympics.' FIFA and the IOC didn't immediately respond to requests for comment about the new Trump travel ban. The 2018 World Cup host Russia let fans enter the country with a game ticket doubling as their visa. So did Qatar four years later. Both governments, however, also performed background checks on all visitors coming to the month-long soccer tournaments. Governments have refused entry to unwelcome visitors. For the 2012 London Olympics, Belarus President Alexander Lukashenko – who is still its authoritarian leader today – was denied a visa despite also leading its national Olympic body. The IOC also suspended him from the Tokyo Olympics held in 2021.
